Medical and scientific advancements in research and clinical experience are leading to improved methodologies in the detection, diagnosis and treatment of bladder cancer. The eight (8) accredited activities provided in this educational offering are intended to provide useful information to the global community of clinicians who deal with bladder cancer in their patient populations.

Multimedia Activities

These multimedia activities provide a random-access learning experience by incorporating the use of slide/audio presentations augmented by fully referenced text. The presentations are then followed by faculty panel roundtable discussions. We hope you enjoy this engaging learning format.

Activity One

Do variants in non-muscle-invasive Bladder Cancer (NMIBC) Matter?
Maximilian Burger, MD University of Regensburg Regensburg, Germany
Includes:
• Panel Introduction
• Faculty Presentation
• Panel Discussion
Start Activity >

Activity Two

Understanding Biomarker Performance for Bladder Cancer Surveillance
Yair Lotan, MD
UT Southwestern Med. Ctr.
Dallas, TX
Includes:
• Panel Introduction
• Faculty Presentation
• Panel Discussion
Start Activity >

Activity Three

Understanding the Spectrum of Tumors after BCG Failure
Ashish Kamat, MD
University of Texas MD Anderson Cancer Ctr.
Houston, TX
Includes:
• Panel Introduction
• Faculty Presentation
• Panel Discussion
Start Activity >

Activity Four

How to treat Bladder Cancer if BCG is unavailable
J.A. Fred Witjes, MD
Univ. Hospital Nijmegen
The Netherlands
Includes:
• Panel Introduction
• Faculty Presentation
• Panel Discussion
Start Activity >
 

Activity Five

What to do now that my patient’s tumor has been molecularly characterized
Arnulf Stenzl, MD
University of Tübingen Medical School
Tübingen, Germany
Includes:
• Panel Introduction
• Faculty Presentation
• Panel Discussion
Start Activity >

Activity Six

T1 High Grade Bladder Cancer
Shahrokh F. Shariat, MD
Medical University of Vienna
Vienna, Austria
Includes:
• Panel Introduction
• Faculty Presentation
• Panel Discussion
Start Activity >

Activity Seven

Role of Neoadjuvant Chemotherapy in Bladder Cancer
H. Barton Grossman, MD
University of Texas MD Anderson Cancer Ctr. Houston, TX
Includes:
• Panel Introduction
• Faculty Presentation
• Panel Discussion
Start Activity >

Activity Eight

Optimal Surveillance for Follow-up of NMIBC
James Catto, MD
University of Sheffield Sheffield, UK
Includes:
• Panel Introduction
• Faculty Presentation
• Panel Discussion
Start Activity >